AR088258A1 - Inhibidores de la pde10 de azetidina 1,3-sustituida - Google Patents
Inhibidores de la pde10 de azetidina 1,3-sustituidaInfo
- Publication number
- AR088258A1 AR088258A1 ARP120103729A ARP120103729A AR088258A1 AR 088258 A1 AR088258 A1 AR 088258A1 AR P120103729 A ARP120103729 A AR P120103729A AR P120103729 A ARP120103729 A AR P120103729A AR 088258 A1 AR088258 A1 AR 088258A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- groups
- alkyl
- heterocycle
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544065P | 2011-10-06 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088258A1 true AR088258A1 (es) | 2014-05-21 |
Family
ID=48044097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103729A AR088258A1 (es) | 2011-10-06 | 2012-10-05 | Inhibidores de la pde10 de azetidina 1,3-sustituida |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9365562B2 (enExample) |
| EP (1) | EP2763672B1 (enExample) |
| JP (1) | JP2014528446A (enExample) |
| AR (1) | AR088258A1 (enExample) |
| AU (1) | AU2012318874A1 (enExample) |
| CA (1) | CA2851082A1 (enExample) |
| TW (1) | TW201321369A (enExample) |
| WO (1) | WO2013052395A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012313888B2 (en) | 2011-09-27 | 2016-03-31 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014078217A1 (en) * | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine pde10 inhibitors |
| EP2919781B1 (en) | 2012-11-15 | 2017-06-28 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
| TW201422610A (zh) * | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
| EP2922543B1 (en) | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
| ES2480341B1 (es) * | 2013-01-24 | 2015-01-22 | Palobiofarma S.L | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10) |
| KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| FR3040057A1 (fr) * | 2015-08-13 | 2017-02-17 | Inventiva | Composes de type azetidine carboxylique |
| US10583269B2 (en) | 2016-06-01 | 2020-03-10 | Becton, Dickinson And Company | Magnetized catheters, devices, uses and methods of using magnetized catheters |
| WO2019046316A1 (en) * | 2017-08-28 | 2019-03-07 | Acurastem Inc. | PIKFYVE KINASE INHIBITORS |
| PT3860998T (pt) | 2018-10-05 | 2024-04-02 | Annapurna Bio Inc | Compostos e composições para o tratamento de condições associadas à atividade do recetor apj |
| WO2021163727A1 (en) * | 2020-02-11 | 2021-08-19 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
| WO2025049402A1 (en) * | 2023-08-28 | 2025-03-06 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4495257B2 (ja) * | 1997-02-19 | 2010-06-30 | バーレツクス ラボラトリーズ インコーポレーテツド | Ｎｏｓ抑制剤としてのｎ−複素環誘導体 |
| EP1499598A1 (en) | 2002-04-18 | 2005-01-26 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| CN102558155A (zh) * | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗 |
| DE102008020113A1 (de) | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| WO2006100461A1 (en) | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
| JP2008540443A (ja) | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン |
| CA2654792A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| PT2698062E (pt) * | 2006-12-28 | 2015-10-19 | Abbvie Inc | Inibidores da poli (adp-ribose) polimerase |
| CA2709203A1 (en) * | 2007-12-13 | 2009-06-18 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| JP2011515462A (ja) | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| MX2012013128A (es) * | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| WO2012044561A2 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
| WO2013028590A1 (en) | 2011-08-25 | 2013-02-28 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
-
2012
- 2012-10-01 JP JP2014534619A patent/JP2014528446A/ja not_active Withdrawn
- 2012-10-01 EP EP12838133.2A patent/EP2763672B1/en active Active
- 2012-10-01 WO PCT/US2012/058220 patent/WO2013052395A1/en not_active Ceased
- 2012-10-01 AU AU2012318874A patent/AU2012318874A1/en not_active Abandoned
- 2012-10-01 CA CA2851082A patent/CA2851082A1/en not_active Abandoned
- 2012-10-01 US US14/349,041 patent/US9365562B2/en active Active
- 2012-10-05 TW TW101137034A patent/TW201321369A/zh unknown
- 2012-10-05 AR ARP120103729A patent/AR088258A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012318874A1 (en) | 2014-05-15 |
| WO2013052395A1 (en) | 2013-04-11 |
| CA2851082A1 (en) | 2013-04-11 |
| EP2763672B1 (en) | 2016-08-10 |
| JP2014528446A (ja) | 2014-10-27 |
| EP2763672A4 (en) | 2015-03-04 |
| US20140256708A1 (en) | 2014-09-11 |
| TW201321369A (zh) | 2013-06-01 |
| EP2763672A1 (en) | 2014-08-13 |
| US9365562B2 (en) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR078153A1 (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| AR095018A1 (es) | Procesos e intermedios para hacer un inhibidor de jak | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) | |
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR115015A1 (es) | Derivados de azaespiro piperazina | |
| AR095267A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| AR085711A1 (es) | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas | |
| AR097772A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediado por actividad quinurenina-3-monooxigenasa | |
| AR093128A1 (es) | Inhibidores de la syk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |